Literature DB >> 23193719

CDC update on pertussis surveillance and Tdap vaccine recommendations.

Thomas A Clark1, Nichole Bobo.   

Abstract

Pertussis is the most poorly controlled bacterial vaccine-preventable disease. Since the early 1980s there has been an increase in reported cases of pertussis. Multiple factors have likely contributed to the increase, including waning immunity, increased recognition, and changes in diagnostic testing and reporting. Of the four combination vaccines used to prevent diphtheria, tetanus, and pertussis, one dose of Tdap should be used to vaccinate preteens as well as teens and adults who have not yet received this booster dose. It is the position of NASN that immunizations, including the Tdap vaccine, are key to primary prevention of diseasefrom infancy through adulthood. The school nurse is in a critical position to create awareness and influence action-related national and state recommendations for the Tdap vaccine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23193719     DOI: 10.1177/1942602X12452443

Source DB:  PubMed          Journal:  NASN Sch Nurse        ISSN: 1942-602X


  7 in total

Review 1.  Bordetella pertussis pathogenesis: current and future challenges.

Authors:  Jeffrey A Melvin; Erich V Scheller; Jeff F Miller; Peggy A Cotter
Journal:  Nat Rev Microbiol       Date:  2014-03-10       Impact factor: 60.633

2.  Is it time to administer acellular pertussis vaccine to childbearing age/pregnant women in all areas using whole-cell pertussis vaccination schedule?

Authors:  Abdoulreza Esteghamati; Shirin Sayyahfar; Yousef Alimohamadi; Sarvenaz Salahi; Mahmood Faramarzi
Journal:  Ther Adv Vaccines Immunother       Date:  2021-05-25

3.  Combined reduced-antigen content tetanus, diphtheria, and acellular pertussis (tdap) vaccine-related erythema nodosum: case report and review of vaccine-associated erythema nodosum.

Authors:  Philip R Cohen
Journal:  Dermatol Ther (Heidelb)       Date:  2013-11-01

4.  Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection.

Authors:  Noelia Olivera; Celina E Castuma; Daniela Hozbor; María E Gaillard; Martín Rumbo; Ricardo M Gómez
Journal:  Biomed Res Int       Date:  2014-05-13       Impact factor: 3.411

5.  Enhanced Bordetella pertussis acquisition rate in adolescents during the 2012 epidemic in the Netherlands and evidence for prolonged antibody persistence after infection.

Authors:  Saskia van der Lee; Susanne P Stoof; Mariette B van Ravenhorst; Pieter G M van Gageldonk; Nicoline A T van der Maas; Elisabeth A M Sanders; Anne-Marie Buisman; Guy A M Berbers
Journal:  Euro Surveill       Date:  2017-11

6.  Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination.

Authors:  Saskia van der Lee; Debbie M van Rooijen; Mary-Lène de Zeeuw-Brouwer; Marjan J M Bogaard; Pieter G M van Gageldonk; Axel Bonacic Marinovic; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

7.  Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines.

Authors:  Han Xu; Jing Huang; Zhaolu Liu; Xin Li; Kangfeng Wang; Erling Feng; Jun Wu; Li Zhu; Kaihu Yao; Chao Pan; Hengliang Wang
Journal:  Vaccines (Basel)       Date:  2021-05-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.